ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong Press release Key Updates August 28, 2017
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Press release Key Updates Mai 31, 2017
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates Press release … co-founder of ProQR and previously served as ProQR’s Chief Innovation Officer from 2014 to 2022. John Maraganore, PhD, a … Juni 01, 2022
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Dezember 05, 2024
Lilly and ProQR to Expand RNA Editing Collaboration Press release … further applications of the Axiomer platform to unlock new innovative treatments for people living with diseases with … developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration,” said Andrew … Dezember 22, 2022
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Januar 29, 2019
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness Press release Key Updates November 13, 2017
ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients Press release Topline data to be presented today at NACFC Oktober 27, 2016
ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials Press release LEIDEN, The Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 23, 2015
ProQR Therapeutics Announces Results for the Third Quarter of 2014 Press release LEIDEN, the Netherlands, Nov. 24, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 24, 2014